Replies to post #359794 on Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

What a relief. As always, thanks for posting Raf. With the holidays fast approaching, it's critical that we get some 80,000-script weeks in the bag. As sales in Germany slowly build, we need the U.S. market to hang in there for another year or so. If, at some point, U.S. scripts start to grow in spite of the generics, then it's blue sky ahead for Amarin.

[bidmark]

I hope that -1 on the generics was an IHubber demanding to switch the generic back to brand!

[lizzy241]

raf, thanks for posting numbers, generics seem to be stagnating.

[MA52TA]

Thanks RAF :-)

[couldbebetter]

Good to see positive numbers! Thank you for posting.

[rafunrafun]

Scripts for week ending November 12, 2021

Overall drug TRx +0.1% w/w

Vascepa
TRx 79,350; -0.6% (-488) w/w; -6.3% y/y
NRx 35,982; +1.3% (+456) w/w; -7.6% y/y
Ref 43,368; -2.1% (-944) w/w; -5.3% y/y

Lovaza (Generic & Brand)
TRx 62,680; +0.2% (+99) w/w; -1.9% y/y
NRx 30,804; +0.8% (+249) w/w; -7.3% y/y
Ref 31,875; -0.5% (-151) w/w; +3.9% y/y

Generic Vascepa
TRx 21,950; +3.8% (+802) w/w; As % of total V: 21.7%
NRx 12,446; +3.5% (+425) w/w; As % of total V: 25.7%
Ref 9,504; +4.1% (+377) w/w; As % of total V: 18.0%

Generic Vascepa by Manufacturer
Hikma - TRx 12,731 (+235); Generic share 58.0%; Total V share 12.6%
Reddy - TRx 9,219 (+567); Generic share 42.0%; Total V share 9.1%

TRx Vascepa + Generic Vascepa
TRx 101,300; +0.3% (+314)
NRx 48,428; +1.9% (+881)
Ref 52,871; -1.1% (-567)